Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 7
---
 GEJ                               
 cancers.                                                                                |
| Data presentation 
 ESMO              | POTOMAC        
 October 2025   | ∗Positive results from the POTOMAC Phase III trial                                      
 showed adding one year of treatment withImfinzito BCG induction and maintenance therapy 
 demonstrated a 32% reduction in the risk of high-risk disease                           
 recurrence or death versus the comparator arm (HR 0.68; 95% CI                          
 0.50-0.93; p=0.0154) in patients with BCG-naïve, high-risk                              
 non-muscle invasive bladder cancer.                                                     |

Lynparza

| Approval 
 CN       | PROpel         
 July 2025      
 New disclosure | ∗In                                                                 
 combination with abiraterone and prednisone or prednisolone for the 
 treatment of adult patients with g/sBRCAm                           
 mCRPC.                                                              |

Tagrisso

| Data presentation 
 WCLC              | FLAURA2        
 September 2025 | ∗Positive results from the final OS analysis of the                     
 FLAURA2 Phase III trial showed Tagrisso with the addition of            
 pemetrexed and platinum-based chemotherapy demonstrated a median OS     
 of nearly four years (47.5 months) compared to approximately three      
 years (37.6 months) forTagrissomonotherapy in the 1st-line treatment of 
 patients with locally advanced or                                       
 metastaticEGFRm NSCLC.                                                  |

BioPharmaceuticals - CVRM

AstraZeneca presented 32 abstracts and 13 posters alongside two hot-line oral presentations at the European Society of Cardiology (ESC) in Madrid, Spain.

baxdrostat

| Data presentation 
 ESC               | BaxHTN       
 August 2025  | ∗Positive results from the BaxHTN Phase III trial                   
 showed that baxdrostat met the primary and all secondary endpoints, 
 delivering meaningful and sustained blood pressure reductions in    
 patients with hard-to-control hypertension. At week 12, the         
 absolute reduction from baseline in mean seated SBP was 15.7 mmHg   
 (95% CI, -17.6 to -13.7) and placebo-adjusted reduction was 9.8     
 mmHg (95% CI, -12.6 to -7.0; p<0.001) for the 2mg dose. Results     
 were consistent across both uncontrolled and